BC-820
BC-820 is a potential therapeutic product that activates both the synthesis of DTA and the protein Tumor Necrosis Factor (TNF) of the cytokine family. Like BC-819, BC-820 penetrates cancerous cells expressing the H19 gene and activates the synthesis of DTA and TNF in a targeted manner.

BC-821
BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA in cells expressing either H19 or the P4 promoter of the target gene IGF2, which, like H19, is expressed only in cancerous cells. This double-promoter method has the potential to reach a larger patient population, as patients expressing either of the target genes will be treatable.

BC-822
This potential therapeutic product seeks to suppress the growth of cancerous cells by re-sequencing a cancer cell's RNA by inserting a small interfering Ribonucleic Acid (siRNA) sequence that prevents the expression of the H19 gene. Like BC-819, the potential therapy would first penetrate cells expressing the H19 gene and then covalently attach the new siRNA sequence.